Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29

Benzinga · 12/17/2025 17:47
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $48 to $29.